NCT06496581 2024-12-20Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)UNICANCERPhase 3 Recruiting500 enrolled
NCT04225299 2020-11-13Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate CancerSteba Biotech S.A.Phase 3 Withdrawn